Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Diffuse large B-cell lymphoma.

Kristin E Hunt1, Kaaren K Reichard

  • 1University of New Mexico, Department of Pathology, Albuquerque, NM 87131, USA.

Archives of Pathology & Laboratory Medicine
|January 10, 2008
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

ICC/WHO-Defined and NGS-Annotated Idiopathic Hypereosinophilia (iHES/iHE): Mutations, Clinical and Treatment Details, and Predictors of Survival.

American journal of hematology·2026
Same author

Absent Cyclin D1 Expression in Myeloid Sarcomas Distinguishes From Malignant Histiocytic Neoplasms: When Morphologic Ambiguity is Deceptive.

The American journal of surgical pathology·2026
Same author

Myelodysplastic Syndromes in VEXAS.

Blood advances·2026
Same author

Therapeutic Outcomes in VEXAS Syndrome: A Multicenter Comparative Cohort of Allogeneic Hematopoietic Stem Cell Transplantation and Hypomethylating Agents.

American journal of hematology·2026
Same author

<i>CSF3R</i>-mutated chronic neutrophilic leukemia: a two-center study of 44 consecutive patients.

Haematologica·2026
Same author

CMML2AML: machine-learning discovery of co-mutations and specific single mutations predictive of blast transformation in chronic myelomonocytic leukemia.

Blood cancer journal·2026
Same journal

Assessing Human Epidermal Growth Factor Receptor 2 in Urothelial Carcinoma: Insights From Clinical Practice Into Scoring Criteria, Histologic Subtypes, and Genomic Characteristics Across Disease Sites.

Archives of pathology & laboratory medicine·2026
Same journal

Cross-Reactivity of TPIT Antibody Clone OTI2G1 in Chordoma: Structural Mechanisms and Diagnostic Implications.

Archives of pathology & laboratory medicine·2026
Same journal

Paracoccidioidomycosis at Autopsy: A Case Series and Literature Review.

Archives of pathology & laboratory medicine·2026
Same journal

Accuracy of Cytology Diagnosis for Well Differentiated Neuroendocrine Tumors: Assessment by the College of American Pathologists Non-Gynecologic Slide Program.

Archives of pathology & laboratory medicine·2026
Same journal

Serum Immunofixation Electrophoresis Guidance Conflict: A Call to Harmonize.

Archives of pathology & laboratory medicine·2026
Same journal

In Reply.

Archives of pathology & laboratory medicine·2026
See all related articles

Diffuse large B-cell lymphoma (DLBCL) subtypes, germinal center B-cell and activated B-cell, show different survival rates. Research is needed to revalidate these differences after adding rituximab to treatment.

Area of Science:

  • Hematology
  • Oncology
  • Pathology

Background:

  • Diffuse large B-cell lymphoma (DLBCL) is a heterogeneous lymphoid malignancy.
  • Morphological subclassification of DLBCL has limited prognostic value and poor reproducibility.
  • Gene expression profiling identified two main DLBCL subtypes: germinal center B-cell (GCB) and activated B-cell (ABC).

Purpose of the Study:

  • To review the clinical, morphological, immunophenotypic, genetic, and gene expression profiling features of de novo DLBCL.
  • To analyze prognostic data from studies conducted before and after the addition of rituximab to chemotherapy.

Main Methods:

  • Review of existing literature on DLBCL classification and prognosis.
  • Analysis of gene expression profiling data and immunohistochemical surrogate markers.

Related Experiment Videos

  • Comparison of survival outcomes in DLBCL subtypes with and without rituximab treatment.

    • Main Results:

    • GCB subtype generally exhibits better survival than ABC subtype in pre-rituximab studies.
    • The impact of rituximab on survival differences between DLBCL subtypes requires revalidation.
    • Immunohistochemical markers can validate GCB and ABC subtypes for clinical use.

    Conclusions:

    • DLBCL subtypes have distinct biological and clinical features.
    • The prognostic significance of DLBCL subtypes may be altered by rituximab therapy.
    • Further studies are essential to guide treatment strategies based on DLBCL subtypes in the rituximab era.